HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bonora, E. Articles by Muggeo, M. Search for Related Content PubMed PubMed Citation Articles by Bonora, E. Articles by Muggeo, M. Social Bookmarking                What's this?

HOMA-Estimated Insulin Resistance Is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic Subjects

Prospective data from the Verona Diabetes Complications Study

From the Endocrinology and Metabolic Diseases, University of Verona Medical School, Verona, Italy

OBJECTIVE—To evaluate whether homeostasis model assessment-estimated insulin resistance (HOMA-IR) is an independent predictor of cardiovascular disease (CVD) in type 2 diabetes.

RESEARCH DESIGN AND METHODS—Conventional CVD risk factors (sex, age, smoking, plasma lipids, blood pressure, and metabolic control) and insulin resistance (estimated by HOMA) were evaluated at baseline in 1,326 patients with type 2 diabetes examined within the Verona Diabetes Complications Study. At baseline and after a mean follow-up of 4.5 years, CVD was assessed by medical history, physical examination, electrocardiography, and echo-Doppler of carotid and lower limb arteries. Death certificates and medical records of subjects who died during the follow-up were carefully scrutinized to identify cardiovascular deaths. In statistical analyses, CVD was an aggregate end point including both fatal and nonfatal coronary, cerebrovascular, and peripheral vascular disease as well as ischemic electrocardiographic abnormalities and vascular lesions identified by echo-Doppler.

RESULTS—At baseline, 441 subjects were coded positive for CVD (prevalent cases). Incident cases numbered 126. Multiple logistic regression analyses showed that, along with sex, age, smoking, HDL/total cholesterol ratio, and hypertension, HOMA-IR was an independent predictor of both prevalent and incident CVD. A 1-unit increase in (log)HOMA-IR value was associated with an odds ratio for prevalent CVD at baseline of 1.31 (95% CI 1.10–1.56, P = 0.002) and for incident CVD during follow-up of 1.56 (95% CI 1.14–2.12, P < 0.001).

CONCLUSIONS—HOMA-IR is an independent predictor of CVD in type 2 diabetes. The improvement of insulin resistance might have beneficial effects not only on glucose control but also on CVD in patients with type 2 diabetes.

Abbreviations: CHD, coronary heart disease • CVD, cardiovascular disease • ECG, electrocardiography • HOMA, homeostasis model assessment • HOMA-IR, HOMA insulin resistance score • WHR, waist-to-hip ratio

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. L. Pande, T. S. Perlstein, J. A. Beckman, and M. A. Creager Association of Insulin Resistance and Inflammation With Peripheral Arterial Disease: The National Health and Nutrition Examination Survey, 1999 to 2004 Circulation, July 1, 2008; 118(1): 33 - 41. [Abstract] [Full Text] [PDF]

				S. S Lund, L. Tarnow, M. Frandsen, U. M Smidt, O. Pedersen, H.-H. Parving, and A. A Vaag Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes Eur. J. Endocrinol., January 1, 2008; 158(1): 35 - 46. [Abstract] [Full Text] [PDF]

				F. Donatelli, A. Vavassori, S. Bonfanti, P. Parrella, L. Lorini, R. Fumagalli, and F. Carli Epidural Anesthesia and Analgesia Decrease the Postoperative Incidence of Insulin Resistance in Preoperative Insulin-Resistant Subjects Only Anesth. Analg., June 1, 2007; 104(6): 1587 - 1593. [Abstract] [Full Text] [PDF]

				G. Targher, L. Bertolini, R. Padovani, S. Rodella, R. Tessari, L. Zenari, C. Day, and G. Arcaro Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients Diabetes Care, May 1, 2007; 30(5): 1212 - 1218. [Abstract] [Full Text] [PDF]

				A. H. Auchincloss, A. V. Diez Roux, D. G. Brown, E. S. O'Meara, and T. E. Raghunathan Association of Insulin Resistance with Distance to Wealthy Areas: The Multi-Ethnic Study of Atherosclerosis Am. J. Epidemiol., February 15, 2007; 165(4): 389 - 397. [Abstract] [Full Text] [PDF]

				C. Berry, J.-C. Tardif, and M. G. Bourassa Coronary Heart Disease in Patients With Diabetes: Part I: Recent Advances in Prevention and Noninvasive Management J. Am. Coll. Cardiol., February 13, 2007; 49(6): 631 - 642. [Abstract] [Full Text] [PDF]

				E. Bonora, S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, J. B. Meigs, R. C. Bonadonna, and M. Muggeo Insulin Resistance as Estimated by Homeostasis Model Assessment Predicts Incident Symptomatic Cardiovascular Disease in Caucasian Subjects From the General Population: The Bruneck Study Diabetes Care, February 1, 2007; 30(2): 318 - 324. [Abstract] [Full Text] [PDF]

				A. MITRAKOU Women's Health and the Metabolic Syndrome Ann. N.Y. Acad. Sci., December 1, 2006; 1092(1): 33 - 48. [Abstract] [Full Text] [PDF]

				the Metascreen Writing Committee The Metabolic Syndrome Is a Risk Indicator of Microvascular and Macrovascular Complications in Diabetes: Results from Metascreen, a multicenter diabetes clinic-based survey Diabetes Care, December 1, 2006; 29(12): 2701 - 2707. [Abstract] [Full Text] [PDF]

				M. M. Chitre and S. Burke Treatment Algorithms and the Pharmacological Management of Type 2 Diabetes Diabetes Spectr, October 1, 2006; 19(4): 249 - 255. [Abstract] [Full Text] [PDF]

				L. G. K. de Aguiar, L. R. Bahia, N. Villela, C. Laflor, F. Sicuro, N. Wiernsperger, D. Bottino, and E. Bouskela Metformin Improves Endothelial Vascular Reactivity in First-Degree Relatives of Type 2 Diabetic Patients With Metabolic Syndrome and Normal Glucose Tolerance Diabetes Care, May 1, 2006; 29(5): 1083 - 1089. [Abstract] [Full Text] [PDF]

				D. A. Lawlor, G. Davey Smith, S. Ebrahim, C. Thompson, and N. Sattar Plasma Adiponectin Levels Are Associated with Insulin Resistance, But Do Not Predict Future Risk of Coronary Heart Disease in Women J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5677 - 5683. [Abstract] [Full Text] [PDF]

				C. H. Saely, S. Aczel, T. Marte, P. Langer, G. Hoefle, and H. Drexel The Metabolic Syndrome, Insulin Resistance, and Cardiovascular Risk in Diabetic and Nondiabetic Patients J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5698 - 5703. [Abstract] [Full Text] [PDF]

				H. Sone, S. Mizuno, H. Fujii, Y. Yoshimura, Y. Yamasaki, S. Ishibashi, S. Katayama, Y. Saito, H. Ito, Y. Ohashi, et al. Is the Diagnosis of Metabolic Syndrome Useful for Predicting Cardiovascular Disease in Asian Diabetic Patients?: Analysis from the Japan Diabetes Complications Study Diabetes Care, June 1, 2005; 28(6): 1463 - 1471. [Abstract] [Full Text] [PDF]

				G. Alberti Introduction to the metabolic syndrome Eur. Heart J. Suppl., June 1, 2005; 7(suppl_D): D3 - D5. [Full Text] [PDF]

				M. Alssema, J. M. Dekker, G. Nijpels, C. D.A. Stehouwer, L. M. Bouter, and R. J. Heine Proinsulin Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality: An 11-year follow-up of the Hoorn Study Diabetes Care, April 1, 2005; 28(4): 860 - 865. [Abstract] [Full Text] [PDF]

				F. Brandou, J.-F. Brun, and J. Mercier Limited Accuracy of Surrogates of Insulin Resistance during Puberty in Obese and Lean Children at Risk for Altered Glucoregulation J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 761 - 767. [Abstract] [Full Text] [PDF]

				B. Hansel, P. Giral, E. Nobecourt, S. Chantepie, E. Bruckert, M. J. Chapman, and A. Kontush Metabolic Syndrome Is Associated with Elevated Oxidative Stress and Dysfunctional Dense High-Density Lipoprotein Particles Displaying Impaired Antioxidative Activity J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4963 - 4971. [Abstract] [Full Text] [PDF]

				E. Bonora, S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, J. B. Meigs, R. C. Bonadonna, and M. Muggeo Population-Based Incidence Rates and Risk Factors for Type 2 Diabetes in White Individuals: The Bruneck Study Diabetes, July 1, 2004; 53(7): 1782 - 1789. [Abstract] [Full Text] [PDF]

				J. P.H. van Wijk and T. J. Rabelink PPAR-{gamma} Agonists: Shifting Attention from the Belly to the Heart? Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 798 - 800. [Full Text]

				M. Fisher Diabetes and atherogenesis Heart, March 1, 2004; 90(3): 336 - 340. [Full Text] [PDF]

				H. E. Resnick, K. Jones, G. Ruotolo, A. K. Jain, J. Henderson, W. Lu, and B. V. Howard Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease in Nondiabetic American Indians: The Strong Heart Study Diabetes Care, March 1, 2003; 26(3): 861 - 867. [Abstract] [Full Text] [PDF]

				T. Tsunekawa, T. Hayashi, Y. Suzuki, H. Matsui-Hirai, H. Kano, A. Fukatsu, N. Nomura, A. Miyazaki, and A. Iguchi Plasma Adiponectin Plays an Important Role in Improving Insulin Resistance With Glimepiride in Elderly Type 2 Diabetic Subjects Diabetes Care, February 1, 2003; 26(2): 285 - 289. [Abstract] [Full Text] [PDF]

				N. Ishizaka, Y. Ishizaka, E. Takahashi, T. Unuma, E.-i. Tooda, R. Nagai, M. Togo, K. Tsukamoto, H. Hashimoto, and M. Yamakado Association Between Insulin Resistance and Carotid Arteriosclerosis in Subjects With Normal Fasting Glucose and Normal Glucose Tolerance Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 295 - 301. [Abstract] [Full Text] [PDF]